PHIBRO-TECH, INC – Trademark Portfolio

Entity Type: 03

PHIBRO-TECH, INC holds 11 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 8 filings in this category. The portfolio also extends into Class 1 (Chemicals) across 2 Nice Classification classes. Currently, 5 trademarks are registered. Notable registered marks include TYPY, CHAMP, AGRI TIN, PHOSTROL, and CHAMP DRY PRILL. The owner is based in FORT LEE, NJ.

ONE PARKER PLAZA

FORT LEE, NJ 10041

11 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

PHIBRO-TECH, INC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (8 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

1
Chemicals (3 filings)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

Frequently Asked Questions

How many trademarks does PHIBRO-TECH, INC have?

PHIBRO-TECH, INC has 11 U.S. trademarks filed with the USPTO. Of these, 5 registered, 2 abandoned, 4 cancelled.

What trademark classes does PHIBRO-TECH, INC file in?

PHIBRO-TECH, INC files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 1 (Chemicals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are PHIBRO-TECH, INC's most well-known trademarks?

PHIBRO-TECH, INC's registered trademark portfolio includes well-known marks such as TYPY, CHAMP, AGRI TIN, PHOSTROL, and CHAMP DRY PRILL. These are among 5 currently registered trademarks in the portfolio.

What is PHIBRO-TECH, INC's trademark registration success rate?

PHIBRO-TECH, INC has a 45% trademark registration rate, with 5 out of 11 resolved applications resulting in successful registration. Currently, 0 applications are pending review.